Accéder au contenu
Merck

Fibroblast growth factor receptor-2 expression in thyroid tumor progression: potential diagnostic application.

PloS one (2013-08-27)
Adriano Redler, Giorgio Di Rocco, Domenico Giannotti, Francesca Frezzotti, Maria Giulia Bernieri, Simona Ceccarelli, Sirio D'Amici, Enrica Vescarelli, Anna Paola Mitterhofer, Antonio Angeloni, Cinzia Marchese
RÉSUMÉ

Fibroblast growth factor receptor-2 (FGFR-2) plays an important role in tumorigenesis. In thyroid cancer it has been observed a FGFR-2 down-modulation, but the role of this receptor has not been yet clarified. Therefore, we decided to examine the expression of both FGFR-2 isoform, FGFR-2-IIIb and FGFR-2-IIIc, in different histological thyroid variants such as hyperplasia, follicular adenoma and papillary carcinoma. Immunohistochemistry and quantitative Real-Time PCR analyses were performed on samples of hyperplasia, follicular adenoma and papillary carcinoma, compared with normal thyroid tissue. Thyroid hyperplasia did not show statistically significant reduction in FGFR-2 protein and mRNA levels. Interestingly, in both follicular adenoma and papillary carcinoma samples we observed a strongly reduced expression of both FGFR-2 isoforms. We speculate that FGFR-2 down-modulation might be an early event in thyroid carcinogenesis. Furthermore, we suggest the potential use of FGFR-2 as an early marker for thyroid cancer diagnosis.